News/ News/ R&D Novartis takes $80M punt on early-stage NASH drug from Pliant Phil Taylor hepatology, licensing, NASH, Novartis, Pliant Therapeutics 0 Comment Novartis has added another non-alcoholic steatohepatitis (NASH) drug candidate to its pipeline via an $80 million licensing deal Share X Novartis takes $80M punt on early-stage NASH drug from Pliant https://pharmaphorum.com/news/novartis-takes-80m-punt-on-early-stage-nash-drug-from-pliant/
hepatology, licensing, NASH, Novartis, Pliant Therapeutics
0 Comment
